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rabbit sera (Original magnification X 400). (ISS= 
Intensity specific staining; NSB = nonspecific 
background) 
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4.3 Plates showing the positive immunostaining of survivin in 
the liver during fetal development of mouse at day 18.  
Panel A) Original magnification x 2.5   Panel B) Arrows 
show the cytoplasmic staining of survivin (Original 
magnification x400) 
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5.1a The effect of different concentration of doxorubicin on 
the relative viability of MCF-7 cell line after 72 hours. 
Each value represents the mean ± s.d. of four independent 
triplicate experiments. Percentage values of cell viability 
was obtained with untreated control cells maintained 
under identical experimental conditions were taken as 
100%. 
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incubation with chemotherapeutic drug. Plate A) Original 
magnification x100, intensity (+++). Plate B) Original 
magnification x400, intensity (+++).  Most of the cells 
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staining of  survivin. There was no predominantly nuclear 
(N>C) staining. The score values in the experiment was 
performed by the specific standard scoring system 
 
5.5a The effect of doxorubicin on the subcellular localization 
of survivin. The localization of the survivin within a cell 
was classified as predominantly nuclear (N>C), nuclear 
and cytoplasmic (N/C), predominantly cytoplasmic 
(C>N), or exclusively cytoplasmic (C). The bars represent 
the mean of four independent experiments with less than 
10% variation. More than 1000 cells were counted per 
experiment according to 5, 1, 0.5, 0.2, 0.1 x PPC. The 
PPC of doxorubicin is 0.5 μg/ml.  Most of the cells 
expressed cytoplasmic staining and only a small 
percentage expressed nuclear-cytoplasmic staining 
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cytoplasmic (C>N), or exclusively cytoplasmic (C). The 
bars represent the mean of four independent experiments 
with less than 10% variation. More than 1000 cells were 
counted per experiment according to 5, 1, 0.5, 0.2, 0.1 x 
PPC. The PPC of doxorubicin is 6 μg/ml.  Most of the 
cells expressed cytoplasmic staining and only a small 
percentage expressed nuclear-cytoplasmic staining 
 
172
5.5c The effect of 5-FU on the subcellular localization of 
survivin. The localization of the survivin within a cell 
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5.5d The effect of TAM on the subcellular localization of 
survivin. The localization of the survivin within a cell 
was classified as predominantly nuclear (N>C), nuclear 
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(C>N), or exclusively cytoplasmic (C). The bars represent 
the mean of four independent experiments with less than 
10% variation. More than 1000 cells were counted per 
experiment according to 5, 1, 0.5, 0.2, 0.1 x PPC. The 
PPC of doxorubicin is 40.0 ng/ml.  Most of the cells 
expressed cytoplasmic staining and only a small 
percentage expressed nuclear-cytoplasmic staining 
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3.1a A micrograph showing the immunostaining of survivin 
(arrows) scoring    ++(++), and in category 3 of positivity 
in breast cancer tissue section with antigen retrieval 
buffer, citrate buffer, pH 6 with dilution of primary 
SUR12A-CFI antibody 1: 1280 and secondary antibody 
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(arrows) scoring  +++ (+), and in category 4 of positivity 
in breast cancer tissue section with  antigen retrieval 
buffer Tris-EDTA pH 9, with dilution of primary  
SUR12A-CFI antibody 1: 1280 and secondary dilution 
antibody 1: 160 (Original magnification X 400)  
 
Note: +++ (+) = intensity of specific staining (intensity of 
background staining).  A mean percentage  of positive  
tumor cells was determined  in at least five areas at  X 
400 magnification and assigned to one of the five 
following categories: (a) 0, < 5%; (b)1, 5-25%; (c)2, 26-
50%, (d) 3, 51-75%;  and (e) 4, > 75%. The intensity  of 
survivin immunostaining was scored as follows: (a) weak, 
+; (b) moderate, ++; (c) intense, +++ 
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3.2a A micrograph showing the immunostaining of survivin 
(arrows) with scoring +++ (+), and in category 3 of 
positivity in colon cancer tissue section with antigen 
retrieval buffer, citrate buffer, pH 6 with dilution of 
primary SUR12A-CFI antibody 1: 1280 and secondary 
antibody dilution  1: 160  (Original magnification X 400)  
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Note: +++ (+) = intensity of specific staining (intensity of 
background staining).  A mean percentage  of positive  
tumor cells was determined  in at least five areas at  X 
400 magnification and assigned to one of the five 
following categories: (a) 0, < 5%; (b)1, 5-25%; (c)2, 26-
50%, (d) 3, 51-75%;  and (e) 4, > 75%. The intensity  of 
survivin immunostaining was scored as follows: (a) weak, 
+; (b) moderate, ++; (c) intense, +++. 
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background staining).  A mean percentage  of positive  
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400 magnification and assigned to one of the five 
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50%, (d) 3, 51-75%;  and (e) 4, > 75%. The intensity  of 
survivin immunostaining was scored as follows: (a) weak, 
+;  (b) moderate, ++;  (c) intense, +++ 
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AN  IMMUNOHISTOCHEMICAL STUDY OF 
 SURVIVIN EXPRESSION IN NORMAL AND IN TRANSFORMED CELLS 
 
ABSTRACT 
 
Survivin is a new member of the inhibitors of apoptosis protein (IAP) family, 
selectively over-expressed in common human cancers but not in normal adult tissues. It 
is also expressed in cancer cell lines. The study was performed generally to investigate 
 xxxv
the basic and clinical roles of survivin in normal and transformed cells. Rabbits were        
immunized with two synthetic oligopeptides, MGAPTLPPAWQP and 
KEFEETAKKVRRAIEQLAAMD amino acids sequences of the survivin molecule. 
Serum antibodies were purified by ammonium sulphate and caprilic acid and their 
specificities were confirmed by immunoblotting and pre-absorption tests against 
survivin positive tissues or synthetic survivin oligopeptides. These antibodies were used 
to detect survivin in normal and transformed cells by immunohistochemistry in 
formalin-fixed paraffin embedded tissue sections, evaluated by a standard scoring 
system and chequerboard analysis. Normal cells were obtained from fetal and adult 
tissues of mouse and rat whilst the transformed cells were obtained from the human 
breast cancer cell line MCF-7 and the infiltrating ductal carcinoma (IDC) of the breast 
patients. In the MCF-7 cell line experiment, the effects of chemotherapeutic drugs 
namely doxorubicin, 5-fluorouracil, cyclophosphamide, and tamoxifen on the apoptosis 
index measured by propidium iodide and acridine orange dyes. The relative cell 
viability was measured by an MTT assay and survivin expression was measured by 
immunocytochemistry. In IDC patients (n=382), survivin expression in tissues was 
analyzed for its correlation with clinicalpathological factors, hormonal status, p53, bcl-2 
and the survival rate. Patients and their tissue blocks were obtained from three general 
hospitals in The East Coast of Malaysia. Autoantibodies to survivin were also 
investigated in the sera of the same IDC patients population (n=57) and were compared 
to the control population (n=44). For the immunohistochemistry assay, four rabbit 
antiserum were produced and tested against survivin. The results of this study indicated 
that the antigen retrieval buffer, pH 9 was superior than pH 6 and optimization 
immunohistochemistry was obtained by chequerboard analysis. Furthermore, it was 
found that survivin is expressed abundantly in normal growing fetal cells but not in 
 xxxvi
normal differentiated adult tissues of mouse and rat. In the MCF-7 cell line, the cell 
viability was reduced in a dose-dependent pattern when incubated with the drugs. The 
IC50 estimation in MCF-7 cell line for doxorubicin was 6.0 µg/ml, cyclophosphamide 
171.1 µg/ml, 5-fluorouracil 0.61µg/ml, and tamoxifen 0.7µg/ml, respectively. It was 
found that most of the MCF-7 cells expressed survivin, predominantly in the cytoplasm. 
The percentages of apoptotic cells were increased with the increased concentrations of 
the drugs.  Among the IDC patients, the expression of survivin was 68.1%, p53 29.6%, 
and bcl-2 43.7%, respectively. There was a significant correlation (p<0.05) between 
survivin expression and lymph node involvement, tumour sizes, p53, bcl-2 expression, 
and survival rate among the IDC patients. Anti-survivin autoantibodies reactivities were 
detected in 7% of the sera of IDC patients but not in normal sera. These autoantibodies 
correlated with the positivity of survivin expression, and with advanced breast cancer. It 
was concluded that survivin was abundantly and prominently expressed during fetal 
development of rat and mouse. The polyclonal antibody SUR12A-CFI recognized rat 
and mouse survivin. It was also concluded that survivin is frequently over-expressed in 
IDC patients, and in most MCF-7 cells. Survivin expression has a predictive value in 
predicting the aggressiveness of the tumour cells suggesting that survivin may be a 
useful tool in assessing a prognosis.             
KAJIAN IMUNOHISTOKIMIA  
 TERHADAP EKSPRESI SURVIVIN DI  
DALAM SEL NORMAL DAN SEL TERTRANSFORMASI 
 
 
ABSTRAK 
 
 
Survivin merupakan ahli baru dalam keluarga protin perencat apoptosis, secara terpilih 
diekspres secara berlebihan dalam kebanyakan kanser tetapi tidak di dalam tisu dewasa 
normal. Ia juga diekspres di dalam rangkaian sel-sel kanser. Kajian ini dilakukan bagi 
 xxxvii
mengkaji secara asas dan klinikal tentang survivin di dalam sel normal dan sel 
tertransformasi. Arnab telah diimunkan dengan sintetik oligopeptida, jujukan asid 
amino, MGAPTLPPAWQP dan KEFEETAKKVRRAIEQLAAMD daripada molekul 
survivin. Antibodi serum ditulenkan dengan ammonium sulfat dan asid caprilik dan 
speksifikasinya telah disahkan dengan teknik immunoblot dan ujian penyerapan awal 
terhadap tisu positif survivin dan sintetik oligopeptida survivin. Antibodi ini telah 
digunakan untuk mengesan survivin di dalam sel normal dan sel tertransformasi 
menggunakan kaedah imunohistokimia pada hirisan tisu formalin-paraffin dan diukur 
menggunakan kaedah sistem pengskoran piawai dan analisis optimasi.  Sel normal 
diperolehi daripada tisu fetus dan tisu dewasa tikus dan mencit manakala sel 
tertransformasi diperolehi daripada rangkaian sel kanser payu dara MCF-7 dan pesakit 
karsinoma infiltrasi kalenjar payu dara. Di dalam kajian rangkaian sel MCF-7, kesan 
dadah kemoterapi iaitu Doxorubicin, 5-Fluorourasil, Cyclophosphamide dan Tamoxifen 
ke atas indek apoptosis yang diukur dengan kaedah propidium iodida dan akridin oren. 
Relatif sel viabiliti diukur dengan ujian MTT dan ekspresi survivin diukur dengan 
kaedah immunositokimia. Korelasi antara faktor klinikopatologi, status hormon, p53, 
bcl-2 dan kadar hidup di kalangan pesakitr kanser payu dara (n=382) telah dianalisa.  
Blok-blok tisu daripada pesakit telah diperolehi daripada tiga hospital utama di Pantai 
Timur. Autoantibodi terhadap survivin juga telah dikaji di dalam serum pesakit kanser 
payu dara (n=57) dan dibandingkan dengan kumpulan kawalan (n=44). Keputusan 
kajian mendapati, empat antiserum telah berjaya dihasilkan dan diuji terhadap survivin 
secara immunohistokimia. Larutan penampan pemulihan antigen pH 9 adalah lebih baik 
berbanding dengan pH 6 dan optimasi telah diperolehi dengan kaedah analisis optimasi. 
Survivin didapati diekspres di dalam sel normal fetus mencit dan tikus yang aktif tetapi 
tidak pada sel normal yang telah membeza. Nilai IC50  bagi rangkaian sel MCF-7 untuk 
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Doxorubixin ialah 6.0 µg/ml, Cyclophosphamide 171.1 µg/ml, 5-Fluorourasil 0.61 
µg/ml dan Tamoxifen 0.7 µg/ml.  Didapati survivin diekspres kebanyakannya di 
sitoplasma. Peratus  sel apoptotik  meningkat dengan peningkatan dos dadah. Di 
kalangan pesakit kanser payu dara, survivin diekspres sebanyak 68.1%, p53 29.6% dan 
bcl-2 43.7%. Terdapat korelasi yang bererti (p<0.05) di antara ekspresi survivin dengan 
metastasis nodus limfa, saiz tumor, p53, bcl-2 dan kadar hidup di kalangan pesakit yang 
dikaji.  Sebanyak 7% autoantibodi terhadap survivin dikesan di kalangan pesakit tetapi 
tidak pada kumpulan kawalan. Autoantibodi didapati berkorelasi dengan ekspresi 
survivin dan tahap akhir kanser.  Kesimpulan kajian ialah survivin banyak diekspres 
pada sel normal yang aktif membahagi dan sel tertransformasi. Antibodi SUR-12A-CFI 
dapat mengesan survivin pada tikus dan mencit. Survivin juga secara berlebihan 
diekspres di kalangan pesakit kanser payu dara dan rangkaian sel MCF-7. Survivin juga 
mungkin boleh digunakan untuk meramal keagresifan sel tumor dan dicadangkan 
survivin boleh menjadi alat untuk membuat penilaian prognosis.     
 1
CHAPTER I 
 
INTRODUCTION 
 
1.1 The cell cycle 
 
1.1.1a The normal cell cycle 
 
Normal cells of multi-cellular organisms can divide as often as once or twice a 
day in vivo. The rate of cell proliferation within any population of cells depends on three 
parameters: a) the rate of cell division (Tc), (b) the fraction of cells within the 
population undergoing cell division (growth fraction), and (c) the rate of cessation of 
cell division due to terminal differentiation or cell death (Andreeff et al., 2000). 
 
Cellular reproduction is a cyclic process in which daughter cells are produced 
through nuclear division (mitosis) and cellular division (cytokinesis). Mitosis (M) and 
cytokinesis are part of the growth-division cycle called the cell cycle (Fig.1.1). Mitosis 
lasts for about 1 hour, and takes a relatively small part of the total cell cycle. Interphase 
is the mitosis preparatory stage which is divided into 3 phases, G1, S, and G2 (Fig 1.1). 
The first gap phase, G1 which lasts for about 6 hours to several days or longer, is a 
period of growth and metabolic activity following a previous mitosis (Fig. 1.1). The 
synthesis phase (S phase) follows G1 and is a period of DNA synthesis, in which the 
DNA is replicated.  Another gap phase, G2 which lasts about 2 hours, follows DNA 
synthesis and precedes the next mitotic division. Certain mature cell types do not 
continue to divide but remain in interphase (in G0). Cells that are permanently in the G0  
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                       . 
 
 
Figure 1.1:  Cell cycle pathways showing its check points and regulators of a normal 
cell.  M=Mitosis, G= Gap, S=Synthesis, R=Restriction (Andreef et al., 
2000;  Li et al., 1998). 
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phase are in a quiescent state and are called post-mitotic (Andreeff et al., 2000; Levine 
1997; Adam et al., 2001; Banks et al., 2000; Bartek & Lukas, 2001;Bursch et al., 2000).  
 
The timing and ordering of cell cycle transitions are dependent on separate 
positive and negative regulatory circuits. The regulatory circuits enforce a series of 
checkpoints, allowing passage only after completion of critical cell cycle events. Two 
classes of regulatory pathways exist, intrinsic and extrinsic. Intrinsic regulatory 
pathways are responsible for the precise ordering of the cell cycle events. Since the 
lengths of S, G2, and M phases in mammalian cells are relatively invariant, the 
transitions between these phases are controlled predominantly by intrinsic regulatory 
pathways. Extrinsic regulatory pathways function in response to environmental 
conditions or in response to detected cell cycle defects. Both types of regulatory 
pathways can use the same checkpoints (Andreeff et al., 2000; Evans &Vousden, 2001). 
 
 When DNA is damaged by alkylating agents or by UV radiation, cells initiate a 
response that includes cell cycle arrest, apoptotic cell death, and transcriptional 
induction of genes involved in DNA repair. Normal cells in G1 phase prior to the 
restriction point (R) will arrest in G1 phase upon sensing DNA damage (Fig. 1.1) 
(Andreeff et al., 2000; Budiharjo et al., 1999; Fernandez et al., 1998; Fu et al., 2004). 
 
1.1.1b  The cell cycle of tumour cell: tumour growth and cell proliferation  
 
Cancer is a disease of accumulation of clonally expanded cells. Tumour cell 
numbers increase, and the tumour burden accounts for the adverse effects on the host 
(Andreeff et al., 2000). Thus, cancer is a disease of uncontrolled proliferation. The 
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mechanisms that underly tumour and normal cell proliferation are very similar 
(Andreeff et al., 2000). Both bcl-2 and p53 play a role in determining tumour growth by 
their effects on apoptosis and cell proliferation (Linjawi et al., 2004). Hence, tumour 
growth is the net result of cell proliferation and cell death (Siziopikou & Schnitt, 2000). 
  
P53 is the guardian or the master brake in the cell cycle. When some cellular 
mechanism goes wrong, the wild p53 will stop the cell from dividing, but if the wild 
p53 is altered to a mutant p53, it can no longer stop the cell from dividing. As the 
situation is not an abnormal control of the cell control but the cell cycle can no longer be 
controlled if there are genetically altered cells (Levine, 1997; Park et al., 1997; Moreno 
et al., 2001; Nakahara et al., 1998; Shiratsuchi et al., 2002). 
 
1.1.2   Apoptosis 
 
Apoptosis or programmed cell death (PCD) is a universal and physiological 
process responsible for removing unwanted, old, damaged, and misplaced cells during 
embryonic development and tissue homeostasis (Sreedhar & Csermely, 2004; Borner, 
2003; Andreeff et al., 2000; Eissa et al., 1999; Strasser et al., 1997). The study of 
apoptosis has emerged from relative obscurity to become a major focus of research 
interest in many areas of medicine in the last decade (Rudin et al., 1997). 
 
Apoptosis is derived from Greek and refers to the dropping or falling of leaves 
from a tree (Sreedhar & Csermely, 2004).  The term was introduced by Kerr et al., 
(1972) to define the morphologic features of the apoptotic process. Some promoter and 
suppressor genes control this process (Sirvent et al., 2004; Roninson et al., 2001). 
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1.1.2.1 The major elements of apoptosis 
 
Apoptosis is well characterized by distinct morphological and physiological 
changes (Sirvent et al., 2004). The p53 protein is also involved in both the extrinsic and 
the intrinsic pathways of apoptosis by initiating apoptosis through mitochondrial 
depolarization and sensitizing cells to inducers of apoptosis (Hofseth et al., 2004). 
Apoptosis is induced by an array of internal and external stimuli or signals and its 
mechanism has several common elements regardless of the ultimate biochemical 
pathways utilized (Kiechle & Zhang, 2002). Apoptosis can be divided into three phases. 
The first phase is the initiation phase (or signalling phase), which involves the activation 
of surface death receptors (extrinsic pathways), mainly the tumour necrosis factor 
(TNF) family members, the mitochondrial pathway (intrinsic pathway) or the initiation 
of apoptosis by other stimuli (e.g., those affecting the endoplasmic reticulum (ER). The 
second is the signal transduction phase (or preparation phase), where activation of 
initiator caspases (caspase-8, caspase-9, caspase-10, and caspase-12) and certain 
kinases/phosphatases takes place. This is followed by the execution phase (or death 
phase), which involves the activation of effector caspases (caspase-3, caspase-6, and 
caspase-7) (Fig. 1.2) (Bronchud et al., 2000; Thornberry & Lazebnik, 1998).  
  
Mammals have two distinct apoptosis signalling pathways, extrinsic and 
intrinsic (Coultas & Strasser, 2003). Signalling through both the extrinsic and intrinsic 
pathways can be modulated by IAPs (inhibitor of apoptosis proteins) such as bcl-2 and 
survivin, which are highly conserved polypeptides that selectively inhibit the activation 
and functional activity of various caspases (Kaufmann & Earnshaw, 2000; Reed, 1999; 
Sanna et al., 2002; Deveraux & Reed, 1999; Campora et al., 2000; Parton et al., 2001).  
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1.1.2.2 The extrinsic apoptotic pathway 
 
This is a receptor-linked pathway that requires the binding of a ligand to a death 
receptor on the cell surface. For example, the cytokine, tumour necrosis factor (TNF), 
binds to the death receptor, TNF receptor type 1 (TNFR1), which recruits two signal 
transducing molecules; TNFR 1-associated protein with a death domain, and a Fas-
associated polypeptide containing a death domain (FADD). This complex then binds to 
procaspase 8 to activate caspase 8, which, in turn initiates the protease cascade leading 
to apoptosis (Fig. 1.2) (Bronchud et al., 2000; Lockshin et al., 2000; Uno et al., 2002). 
 
1.1.2.3  The intrinsic apoptotic pathway 
 
This pathway is mediated by the mitochondrial release of cytocrome c (Kiechle 
& Zhang, 2002; Pruschy et al., 2001).  It is mainly activated when damaged DNA is not 
sensed and repaired by checkpoint genes. Initiation of apoptosis may occur immediately 
or it may be delayed following the DNA damage. The response may or may not be 
dependent on the presence of the nuclear transcription factor, p53. When p53 is 
upregulated, it is activated by the phosphorylation of serine 46 by the homeodomain–
interacting protein kinase-2, and the two proteins cooperate in the activation of the p53–
dependent transcription. (Bronchud et al., 2000; Levine 1997). Proteins induced by p53 
include Bax, a bcl-2 homologous protein, which oligomerizes and forms pores in the 
outer mitochondrial membrane, resulting in either a decrease in the inner mitochondrial 
transmembrane  potential or  opening of  the voltage–dependant  anion  channel, 
releasing   cytochrome c  from  the  space between  the  inner  and  outer    
mitochondrial  membranes   (Heiser et al., 2004).  Cytosolic  cytochrome  c induces  the              
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formation of the multisubunit apoptosome composed of apoptotic protease  activating 
factor-1 (Apaf-1), procaspase 9 and either ATP or dATP. Caspase 3 then mediates the 
apoptotic cascade (Heiser et al., 2004; Bronchud et al., 2000). IAPs of both cellular and 
viral origin have been identified to be intrinsic cellular suppressors of apoptosis that 
block the apoptotic program in response to viral infection or other forms of stresses such 
as survivin (Pruschy et al., 2001; Li & Li, 2000; Thomas, 2000; Shu et al., 1997). 
 
1.1.2.4  Cell morphology and physiological changes during apoptosis 
 
The process of apoptosis involves a cell dying in the midst of surviving cells, in 
contrast to necrosis, which involves clusters of dying cells in an area associated with an 
inflammatory infiltrate. Apoptosis occurs as a single cell death surrounded by healthy 
cells. The morphological changes in apoptosis can be seen by light microscopy, and 
have been characterized further by electron microscopy (Archer et al., 2000). These 
include nuclear (chromatin) condensation with the chromatin forming clumps that 
gather adjacent to the nuclear membrane (nuclear periphery). Furthermore, the 
cytoplasm condenses leading to cell shrinkage due to contraction of the cell and loss of 
volume, and to cell rounding due to loss of adhesion to surrounding cells and membrane 
blebbing. These bodies with condensed nuclear chromatin and, once released into the 
extra-cellular space, are rapidly ingested by phagocytic cells (Coultas & Strasser, 2003; 
Robertson et al., 2000; Wylie & Currie, 1980; Gonzalez-Campora et al., 2000).   
 
 The major physiological changes comprise fragmentation of nuclear DNA due 
to activation of specific endonucleases cleaving nuclear DNA into 80-200 
oligonucleosomal fragments, and the activation of caspases, resulting in partially 
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digested  proteolytic protein products (Sreedhar & Csermely, 2004; Bronchud et al., 
2000). This process produces cell breaking into several fragments of nuclei and 
cytoplasm or both nuclei and cytoplasm, known as apoptotic bodies (Sirvent et al., 
2004). Thus, DNA fragmentation is a characteristic biochemical marker of apoptosis.  
 
1.1.3 Components of the apoptotic pathways 
 
The key elements which execute the apoptotic process have been studied 
(Borner, 2003). Over the years, many components of the apoptotic pathways have been 
characterized, revealing apoptosis to be a highly complex process. However, a pattern is 
emerging with a series of early events that depend on the initial stimulus, followed by a 
common pathway involving a series of cysteine proteases, the caspases. This common 
pathway ultimately results in DNA fragmentation and morphological changes associated 
with apoptosis. Mitochondria have emerged as having a central role in the process and 
its regulation, with the bcl-2 family of proteins playing a particularly important part 
(Strasser et al., 1997; Kaufman & Gores, 2000; King & Cidlowski, 1995). 
 
1.1.3.1  The caspase death proteases  
 
Caspase is a nomenclature referring to ICE/CED-3 cysteine proteinase family 
having a central role during cell death (Suzuki et al., 2001) and in executing the process 
of apoptosis (Fig. 1.2) (Borner, 2003). In mammals, 14 members of the caspase family 
have been identified which cleave their substrates after aspartic acid (Asp). Activation 
of pro-caspases requires two caspases cleaved at the aspartic acid (Asp) residues 
(Strasser et al., 1997). These cleavages remove the amino-terminal pro-domain and 
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separate the large and small catalytic subunits. Once activated, caspases can process and 
activate their own subunits and other pro-caspases (Bossy-Wetzel & Green, 1999). 
Caspase activation  is not reversible and leads to cell apoptosis (Gompel et al., 2004). 
 
These enzymes are minimally active in healthy cells and require further 
activation in response to apoptotic stimuli such as ionizing radiation, chemotherapeutic 
drugs, and death receptor ligands (Shi, 2002; Alarcon & Ronai et al., 2002; Pruschy et 
al., 2001). They are divided into two categories; initiator caspases and effector caspases. 
The former includes caspase-2, caspases 8- to 10, and caspase-12, which are activated in 
response to a cell death signal, and the latter includes caspase-3, caspase-6 and caspase-
7 which transmit the signal activating the cascade that results in DNA fragmentation and  
cell death (Subsection 1.1.2.4)  (Kawamura et al., 2003;  Earnshaw et al., 1999). 
 
1.1.3.2 Cytochrome c 
 
Cytochrome c is a protein that is normally stored in the intermembrane space of 
mitochondria (Scorrano et al., 2003). When the cell receives an apoptotic signal, 
cytochrome c crosses the outer mitochondrial membrane and accumulates in the cytosol 
where its functions as a cofactor in the activation of caspases (Fig. 1.2) (Bossy-Wetzel 
& Green, 1999). Cytochrome c triggers a post-mitochondrial pathway forming an 
oligomeric complex of cytochrome c/ apoptotic protease activating factor-1 (Apaf-
1)/caspase-9, the “apoptosome”, which activates the initiator caspase-9 to subsequently 
cleave the effector caspase-3 and caspase-7  to cause nuclear fragmentation (Scorrano et 
al., 2003; Kaufmann & Earnshaw, 2000). The treatment of HeLa cells with 
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staurosporine, a potent pro-apoptotic agent, causes the release of cytochrome c from the 
mitochondria into the cytosol (Kaufmann & Earnshaw, 2000; Michalides, 1999). 
 
1.2  Survivin 
 
Survivin is a 16.5-kDa protein also known as AP14 or BIRC5. It is an 
intracellular protein that inhibits apoptosis and regulates cell division and belongs to the 
inhibitors of apoptosis (IAP) gene family (Verdacia et al., 2000; Altieri, 2001). 
Members of the IAP family prevent cells from apoptosis, by inhibiting caspases (Fig. 
1.2) (Wojcik et al., 2002; Yamamoto & Tanigawa, 2001). Survivin was discovered in 
1997 by hybridization screening of a human genomic library with the cDNA of the 
effector cell protease receptor-1 (EPR-1) (Ambrosini et al., 1997). The survivin gene 
spans 15 kb, and is located on chromosome 17 t band q25. Survivin has an unusual 
relationship to EPR-1 in that its sequence is complementary to and in the reverse 
orientation of EPR-1. The coding strand of survivin contains an open reading frame of 
426 nucleotides, and encodes a protein of 142 amino acids (Chiou et al., 2003). 
  
Survivin over-expression in vivo increases cell resistance to apoptosis (Chiou et 
al., 2003).  This conclusion has been proven by the study of Grossman et al., (2001a) 
when transgenic expression of survivin in epidermal keratinocytes significantly reduced 
the number of apoptotic cells in the epidermis following exposure to ultraviolet (UV) 
irradiation. Conversely, inhibition of survivin  expression in vitro, by treatment with 
antisense survivin oligonucleotide, increased the susceptibility of HeLa cells to 
receptor-mediated apoptosis, and the human neural tumour cell lines to induced 
apoptosis, MSN and TC620 (Shankar et al., 2001). 
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Survivin appears to have an important role in regulating apoptosis at the cell 
cycle checkpoint(s). Its expression is highly cell cycle-regulated, and is detectable in the 
nucleus selectively at the G2/M phase (Li et al., 1998). Transcription of survivin has 
been shown to be directly repressed by wild-type  p53, another cell cycle checkpoint-
regulating protein that induces apoptosis  (Mirza et al., 2002). When acute 
lymphoblastic leukemia cells are treated with doxorubicin, which causes accumulation 
of wild type p53, the result is a dramatic down-regulation of survivin, depletion of cells 
in the G2/M phase of the cell cycle, and increased apoptosis (Zhou et al., 2002). 
 
In addition, survivin appears to be important for cell cycle progression. 
Disruption of survivin by antisense targeting HeLa cells results in spontaneous 
apoptosis and aberrant mitosis, as well as an increase in caspase-3 activity at mitosis. 
Disruption of survivin in cell lines by both  antisense targeting and survivin antibodies 
also induces polyploidy and aneuploidy as a result of cytokinesis failure and the 
premature onset of anaphase. In vivo, survivin is also required for cell division.  
Homozygous knockout of the survivin gene in mouse embryonic stem cells resulted in 
disrupted microtubule formation and polyploidy during development, which culminated 
in early embryonic lethality (Uren et al., 2000).  
 
1.2.1 Structure and function of survivin 
The structure of human survivin, as determined by X-ray crystallography, 
reveals the presence of an amino-terminal globular zinc finger domain, which includes 
the BIR motif, and a long carboxy-terminal helix separated by a short linker segment, 
important for dimerization (Rodriguez et al., 2002). The structure of survivin is 
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intimately linked with its function as an inhibitor of apoptosis. The amino terminal 
portion of survivin consists of three alpha helices (residues 14-21, 31-41, 68-80) and 3 
beta-sheets (residues 43-45, 55-58, 61-64), which closely resemble the BIR domain that 
is conserved in the IAP family (Fig 1.3). The BIR domains of IAP family members are 
involved in the function of these proteins as inhibitors of apoptosis (Verdecia et al., 
2000).  A mutation in the BIR domain, T34A, which inhibits phosphorylation of 
survivin by p34-cyclin B1, abrogates the ability of survivin to inhibit apoptosis (Chiou 
et al., 2003).  
Three different isoforms of this protein have been identified: survivin (142 aa), 
survivin-2B (165 aa) and survivin-ΔEx3 (137 aa) (Mahotka et al., 1999). Survivin and 
survivin-2B are located in the cytoplasm whereas survivin-ΔEx3 is located in the 
nucleus. Another isoform was reported in 2004 by Badran et al. 2004 designated as 
survivin 3B (120 aa) in human adenocarcinoma cell lines.  It is likely that survivin-3B 
possesses anti-apoptotic activity. Survivin-ΔEx3 has anti-apoptotic properties whilst 
survivin-2B with markedly reduced anti-apoptotic properties (Badran et al., 2004). It 
was reported that the localization in distinct cellular compartments of different nuclear-
cytoplasmic variants might constitute a regulatory mechanism for the activity of 
different splice variants of survivin.  The different isoforms of survivin is believed to 
play a distinct role in cancer and therefore that such a role may be partially determined 
by their differential nuclear-cytoplasmic transport and localization (Rodriguez et al., 
2002).  
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Figure 1.3: The overall architecture of human survivin. a, Ribbon representation of the 
survivin dimer. The Zn 2+ ion is shown as a shaded sphere. Coordination 
bonds are shown as dotted orange spheres. One monomer is blue; the other is 
rose. b, Orthogonal view of the ribbon representation shown in (a). c, 
Perspective and close up view of the Zn2+ binding site on one survivin 
monomer. The depicted orientation corresponds to that pictured in (a). 
(Verdecia et al., 2000) 
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1.2.2 The mechanism of survivin inhibition of apoptosis 
 
Survivin is identified as an intrinsic cellular regulator that plays an important 
role in the suppression of apoptosis by either directly or indirectly inhibiting the activity 
of caspases (Hikita et al., 2002; Badran et al., 2003; Badran et al., 2004; Bao et al., 
2002; Honda et al., 2003; Kuttler et al., 2002; Li et al., 1998; Song et al., 2004; Song et 
al., 2003). Several IAP family members have been shown to suppress apoptosis by 
direct inhibition of caspases via the BIR domains.  The structure of survivin has been 
compared to another IAP family member, XIAP, which contains three BIR domains 
(Tran et al., 1999; Otaki et al., 2000; Shinozawa et al., 2000; Sohn et al., 2003).  XIAP 
inhibits caspase-3 and caspase-7 via a linker region between the first two domains, and 
also binds to and inhibits caspase-9 through its third BIR domain (BIR3). The BIR 
domain of survivin appears to be closely related in its three dimensional structure to the 
BIR3 domain of XIAP, suggesting the possibility that survivin binds caspase-9. 
Survivin has a capability to bind to caspases and modulate their functions (Kawamura et 
al., 2003; Sandler et al., 2002; Sarela et al., 2001; Wheatley et al., 2001; Mahotka et al., 
2002; Kornacker et al., 2001; Krieg et al., 2002). The interaction between survivin and 
caspase-9, and the functional implication of this interaction have been studied through 
mutagenesis. Loss of phosphorylation at threonine 34 on the T34A mutant of survivin 
results in the dissociation of an immunoprecipitable survivin-caspase-9 complex on the 
mitotic apparatus, allowing caspase-9 dependent apoptosis to occur (Chiou et al., 2003; 
Wall et al., 2003; Li et al., 1999; Lu et al., 2004; Fortugno et al., 2003). 
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1.2.3 The role of survivin in cell division 
 
Recent reports demonstrated how survivin may act in regulating cell division. 
During the cell cycle, survivin is first detected on the centromere at 
prophase/metaphase. It is also present in the spindle midzone during 
anaphase/telophase, but is no longer detected by the end of telophase (Li et al., 1998: 
Uren et al., 2000). Furthermore, it was indicated that survivin remains localized in 
kinetochores until metaphase, then in the spindle midzone during anaphase, and in the 
cleavage plane during telophase.  The kinetochore is a DNA-protein complex that 
assembles on the centromere and its required for attachment of the microtubules during 
mitosis (Uren et al., 2000). These localization patterns resemble those of the inner 
centromere proteins (INCENP), TD-60, and Aurora B, which are known as 
chromosomal passenger proteins. Thus, based on its localization during the cell cycle, it 
has been postulated that survivin may be an additional chromosomal passenger protein. 
These four proteins are the only mammalian passenger proteins known to date, which 
are carried on the chromosomes to the center of the cell at metaphase, in the plane of the 
future cleavage furrow, and are important for cytokinesis and chromosomal movements 
during cell division (Chiou et al., 2003). It was concluded that the primary role of 
survivin is to regulate chromosome segregation and cytokinesis  (Uren et al., 2001) 
 
1.2.4 Survivin expression in cell lines, and in embryonic, fetal, and normal adult   
            tissues 
 
The regulation of apoptosis is critical for normal embryonic development and for 
homeostasis in adult tissues (Grossman et al., 2001b). In animals, survivin is strongly 
expressed in embryonic and fetal organs, but is undetectable in most terminally 
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differentiated normal tissues (Mori et al., 2002). Uren et al., (2001) found that survivin 
is expressed in mouse embryos. In the mouse model, survivin was found to be elevated 
at the G2/M phase of the cell cycle during liver regeneration (Deguchi et al., 2002). Kim 
et al., (2003) reported that survivin is strongly expressed at the bottom of mouse 
embryonic intestinal crypts. At the protein level, survivin was also detected during all 
stages of early embryos of mice (Kawamura et al., 2003; Jaskoll et al., 2001). 
 
The expression of survivin in normal human adult tissues, appeared only in a 
few published reports, contrary to numerous reports examining the role of survivin in 
cancer (Chiou et al., 2003). However, its expression has been reported in a few normal 
growing adult human tissues, including thymus (Kobayashi et al., 2002), colonic 
mucosa (Gianani et al., 2001), placenta (Shiozaki et al., 2003; Lehner et al., 2001), bone 
marrow (Altieri & Marchisio, 1999), and keratinocytes of the basal layer of the skin 
(Grossman et al., 2001a; O’Driscoll et al., 2003; Chiodino et al., 1999).  
 
During human development, survivin is expressed in the fetal lung, heart, liver, 
kidney, and gastrointestinal tract, and in fetal tissues where apoptosis occurs, such as the 
stem cell layers of stratified epithelia, endocrine glands, pancreas and thymic medulla. 
In all of these studies, survivin was not found in normal adult tissues. These findings 
suggest that the regulation of cell division and the anti-apoptosis functions of survivin 
are important not only during early development, but also during cancer progression 
(Chiou et al., 2003). 
 
In cell lines, it was reported that  survivin was expressed in HeLa cells (Uren et 
al., 2001), human breast cancer cell line, MCF-7 (Tanaka et al., 2004), melanoma cell 
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lines (Ambrosini et al., 1998; Grossman et al., 1999), a lung adenocarcinoma cell line 
(Olie et al., 2000), neuroblastoma and oligodendroglioma cell lines (Shankar et al., 
2001), a murine thymic lymphoma cell line (Kanwar et al., 2001) and a colorectal 
cancer cell line (Mesri et al., 2001), human colon adenocarcinoma cells, HT29 
(Yamamoto et al., 2002). 
 
1.2.5 Survivin and cancer 
 
One of the most significant features of survivin is its differential distribution in 
cancer compared to normal tissue. Over-expression of survivin has been demonstrated 
in tumours of the lung, breast (Zhang et al., 2004), esophagus, pancreas, bladder, uterus, 
cervix, ovary (Mei et al., 2001; Tarkowski et al., 2001; Tao et al., 2004), large-cell non-
Hodgkin’s lymphoma, leukemias (Schlette et al., 2002; Mori et al., 2002; Carter et al., 
2001; Carter et al., 2003), neuroblastomas, melanomas, gastric (Li et al., 2004; Lu et al., 
1998; Yu et al., 2002), colon (Sarela, et al., 2000; Sarela et al., 2001; Yang et al., 2004), 
stomach, liver (Chiou et al., 2003), oral (Muzio et al., 2004; Muzio et al., 2003; Muzio 
et al., 2001), thyroid (Sugawara et al., 2002), and in laryngeal squamous cell (Dong et 
al., 2002). 
  
Despite its role in mitosis, it is clear that the over-expression of survivin in 
cancer does not simply reflect the presence of a higher number of proliferating cells.  In 
melanoma, survivin expression was indistinguishable in cases with low or high mitotic 
index.  In addition, the fact that survivin is typically observed in nearly all tumour cells, 
and  not  just in  the  mitotic  fraction,  suggests  that  expression  of  the survivin gene is  
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deregulated in cancer, albeit still retaining cell-cycle periodicity in mitosis (Chiou et al., 
2003; Daidone et al., 2001; Endoh et al., 2001; Frost et al., 2002; Gu & Lin, 2004). 
 
In certain cancers, two types of molecular abnormalities have been reported that 
might contribute to aberrant survivin expression.  Gain of chromosome 17q is the most 
common genetic abnormality in neuroblastoma, where amplification of the survivin 
locus on 17q25 has been detected by fluorescence in situ hybridization (Chiou et al., 
2003; Takai et al., 2002). In addition, survivin exon1 sequences are largely silenced by 
methylation in normal ovaries, but become de-methylated, and thus trancriptionally 
active, in most ovarian cancers, leading to the over-expression of survivin (Hattori et al., 
2001). However, given the widespread survivin over-expression in many types of 
cancer, it is plausible that multiple oncogenic signalling pathways might converge on 
the reactivation of the survivin gene in neoplasia (Chiou et al., 2003).   
 
The role of survivin in many cancers has been reported in numerous 
publications, but little has been published about the role of survivin in breast cancer. A 
few reports have shown the expression of survivin in breast cancer ranging from 60% to 
72.% (Zhang et al., 2004; Kennedy et al., 2003; Tanaka et al., 2000). 
 
1.2.6 Clinical significance of survivin  
 
Recently, survivin has emerged as a diagnostic and prognostic marker and a 
potential drug target because it is predominantly overexpressed in most cancer types.  
The role of survivin in the inhibition of apoptosis in breast cancer has not been clearly 
established. Furthermore, only a few reports have highlighted the clinical significance of 
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survivin. Further investigations of survivin during tumour growth and progression may 
yield important insights into its functional role(s) in carcinogenesis and allow the 
development of important therapeutic strategies for combating cancer.  
 
1.2.6.1 Prognostic value of survivin in cancer 
 
Assessment of prognosis is important in patients with malignancies because its 
results serve to separate a large heterogeneous population into smaller populations with 
more concisely predictable outcome (Hayes, 2000). In the majority of neoplasms 
investigated for survivin expression including breast, lung, colorectal, gastric, liver, 
bladder and kidney cancers, neuroblastoma, gliomas, soft tissue sarcomas and 
hematological malignancies, high levels of the IAP proteins were predictive of tumour 
progression, either in terms of disease-free survival or overall survival, thus providing 
prognostically relevant information (Zaffaroni & Daidone 2002; Altieri 2001; Altieri & 
Marchisio 1999). 
 
1.2.6.2  Survivin as a therapeutic target in cancer 
 
Two general considerations make survivin an attractive therapeutic target in 
cancer: it is selectively expressed in tumour cells and it is required for their viability 
(Chiou et al., 2003; Altieri, 2003b; Ueda et al., 2002; Sasaki et al., 2002; Poetker, 2002; 
Pizem et al., 2004; Iurlaro et al., 2004; Guan et al., 2004).  Results obtained by different 
studies aimed at targeting survivin by means of different approaches demonstrated that 
inhibition of this cell survival factor promotes some favourable biological effects 
(Zaffaroni & Daidone 2002; Altieri, 2003a; Altieri 2004; Tsurama et al., 2004).  
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There are several therapeutic strategies targeted to survivin  including the use of  
antisense oligonucleotides; natural antisense (EPR-1 cDNA), oligonucleotide 4003, and 
oligonucleotides 903 and 904 (Ambrosini et al., 1998; Grossman et al., 1999; Olie et 
al., 2000; Shankar et al., 2001), dominant negative mutants: Cys 84 Æ Ala, Thr 34 Æ 
Ala, and Cys 84 Æ Ala (Grosman et al., 1999; Grossman et al., 2001a; Mesri et al., 
2001b; Kanwar et al., 2001), and ribozymes (hammerhead ribozymes) (Pennati et al., 
2002). The biological effects in vitro and in vivo using these therapeutic strategies 
demonstrated  as decrease in cell proliferation, an increased spontaneous apoptosis and 
an enhanced  efficacy of several types of conventional treatments including 
chemotherapy, radiotherapy and immunotherapy (Zaffaroni & Daidone 2002). 
 
1.3  Bcl-2 
1.3.1 Structure and biological functions of bcl-2 
 
B-cell lymphoma-2 protein (Bcl-2) is the first known regulator of cell death 
(Heiser et al., 2004). The bcl-2 family proteins are important regulators of apoptosis in 
mammalian cells (Schinzel et al., 2004). Bcl-2 is an anti-apoptotic protein (Townsend et 
al., 2002;  Giatromanolaki et al., 2001) and is a proto-oncogone (Formby et al., 1999;  
Strasser et al., 1997) that resides on the cytoplasmic face of the mitochondrial outer 
membrane, in the endoplasmic reticulum and in the nuclear envelope (Mullauer et al., 
2001; Robertson et al., 2000; Schinzel et al., 2004).  Bcl-2 is an acronym for the B-cell 
lymphoma/leukemia-2 gene which was identified at the site of the t(14;18) 
chromosomal translocation, occurring in 85% of diffused B-cell lymphomas (Joosens et 
al., 1998;  Strasser et al., 1997).  
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The bcl-2 inhibits apoptosis (Eissa et al., 1999) by blocking the release of 
cytochrome c from mitochondria, thereby preventing Apaf-1 (apoptotic protease-
activating factor-1) and consecutive caspase activation (Fig. 1.2). The bcl-2 may also 
inhibit apoptosis by binding to the pro-apoptotic molecules Bax and bcl-xs  (Mullauer et 
al., 2001).  
 
A number of proteins that are structurally related to bcl-2 (Bcl-2 protein family) 
have been discovered in mammals, birds, frogs, nematodes and viruses and can be sub-
divided into two groups. The first group includes those that inhibit apoptosis 
(mammalian BcLxL, Bcl-w, A1, Mcl-1, nematode Ced-9, adenovirus E1B19kD, Epstein 
Barr Virus (EBV)  BHRF1, African Swine Fever Virus LMW5-HL, Human Herpes 
Virus 8 KSBcl-2 and Herpes Virus Saimiri ORF16). The second group includes those 
that enhance apoptosis (Bax, Bcl-xS the product of alternative splice variant of the bcl-x 
gene, Bad, Bak, Bik/Nbk, Bid and Harakiri  (Strasser et al., 1997). The bcl-2 family of 
proteins appears to be involved in either enhancing or opposing the apoptotic process. 
 
In most situations, the mitochondria act as focal points in the apoptotic pathway 
and provide convenient positions for regulatory molecules to intervene. In cell free 
systems, nuclear condensation and DNA fragmentation were found to be dependent on 
the presence of mitochondria and inhibited by bcl-2 (Heiser et al., 2004). 
 
Bcl-2 plays a crucial role in maintaining the viability of cells that are meant to be 
long-lived such as peripheral lymphocytes (Strasser et al., 1997). The involvement of 
bcl-2 in apoptosis was first seen indirectly when it was noted to prolong cell survival. 
Immature pre-B cells dependent on IL-3 for survival in culture were noted to persist 
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despite IL-3 withdrawal when the cells were transfected with bcl-2, an effect  that 
seemed to occur without cell proliferation. This persistence was later shown to be due to 
the ability of bcl-2 to block apoptosis (Bossy-Wetzel & Green, 1999). 
The bcl-2 family of proteins is also involved in embryogenesis where it controls 
developmentally programmed cell death during tissue differentiation. After birth, bcl-2 
and its relatives play critical roles in regulating programmed cell death in the 
haematopoietic system, tissue homeostasis and mammary gland involution (Coultas & 
Strasser, 2003). 
 
1.3.2 Bcl-2 and its role in breast cancer   
 
In normal breast, bcl-2 is expressed in the non-pregnant and non-involuting 
mammary epithelium. Bcl-2 expression has previously been reported in normal breast 
ductal cells where it is supposed to be involved in the hormonal regulation of 
hyperplasia and involution (Vetrani et al., 1995). Bcl-2 is thought to be expressed 
through hormone-dependent pathways (Ioachim et al., 2000; Vetrani et al., 1995) such 
as estrogen and progesterone (Park et al., 2002).  
 
The exact mechanism and the effect of the down regulation of bcl-2 expression 
on breast cancer cells are not clearly defined (Park et al., 2002). In breast cancer, bcl-2 
expression appears to be inversely correlated with the presence of p53 mutations in its 
pathways (Joosens et al., 1998; El-Ahmady et al., 2002; Takei et al., 1999; Van-Slooten 
et al., 1998). 
 
